DD297960A5 - Indenoindolverbindungen ii - Google Patents

Indenoindolverbindungen ii Download PDF

Info

Publication number: DD297960A5
Authority: DD; German Democratic Republic
Prior art keywords: tetrahydro; indole; cis; formula; thii
Prior art date: 1989-06-22

Application number

DD90341939A

Other languages

German (de)

English (en)

Inventor

Malcolm Sainsbury

Howard G Shartzer

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-22

Filing date

1990-06-21

Publication date

1992-01-30

1990-06-21 Application filed by ��@��@��k��, ��@��@��k�� filed Critical ��@��@��k��

1992-01-30 Publication of DD297960A5 publication Critical patent/DD297960A5/de

Links

RXXXUIOZOITBII-UHFFFAOYSA-N indeno[1,2-g]indole Chemical class C1=C2C=CC=CC2=C2C1=C1N=CC=C1C=C2 RXXXUIOZOITBII-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 97
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 53
125000000217 alkyl group Chemical group 0.000 claims abstract description 41
239000001257 hydrogen Substances 0.000 claims abstract description 38
238000000034 method Methods 0.000 claims abstract description 29
150000002431 hydrogen Chemical class 0.000 claims abstract description 19
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 19
125000003545 alkoxy group Chemical group 0.000 claims abstract description 18
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 13
229910052736 halogen Inorganic materials 0.000 claims abstract description 7
150000002367 halogens Chemical class 0.000 claims abstract description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 455
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 232
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 223
239000000203 mixture Substances 0.000 claims description 47
238000006243 chemical reaction Methods 0.000 claims description 42
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 27
-1 2-substituted-1-indanone Chemical class 0.000 claims description 26
230000009467 reduction Effects 0.000 claims description 20
230000008569 process Effects 0.000 claims description 15
238000007126 N-alkylation reaction Methods 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 12
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
150000002475 indoles Chemical class 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical class C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 claims description 5
230000003647 oxidation Effects 0.000 claims description 5
238000007254 oxidation reaction Methods 0.000 claims description 5
LKNKQSIPELBEKH-UHFFFAOYSA-N 5,6-dihydro-1h-indene Chemical compound C1CC=C2CC=CC2=C1 LKNKQSIPELBEKH-UHFFFAOYSA-N 0.000 claims description 4
238000005804 alkylation reaction Methods 0.000 claims description 4
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
229910052744 lithium Inorganic materials 0.000 claims description 4
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
230000029936 alkylation Effects 0.000 claims description 3
238000005903 acid hydrolysis reaction Methods 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
230000007062 hydrolysis Effects 0.000 claims description 2
238000006460 hydrolysis reaction Methods 0.000 claims description 2
230000000087 stabilizing effect Effects 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims 6
238000006641 Fischer synthesis reaction Methods 0.000 claims 2
UFERIGCCDYCZLN-UHFFFAOYSA-N 3a,4,7,7a-tetrahydro-1h-indene Chemical compound C1C=CCC2CC=CC21 UFERIGCCDYCZLN-UHFFFAOYSA-N 0.000 claims 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
239000000470 constituent Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000001465 metallisation Methods 0.000 claims 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims 1
229940067157 phenylhydrazine Drugs 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 abstract description 12
125000003282 alkyl amino group Chemical group 0.000 abstract description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 130
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 120
239000000243 solution Substances 0.000 description 105
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 61
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
239000007787 solid Substances 0.000 description 56
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
235000019439 ethyl acetate Nutrition 0.000 description 45
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
239000002904 solvent Substances 0.000 description 44
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 43
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
238000002844 melting Methods 0.000 description 27
230000008018 melting Effects 0.000 description 27
239000011734 sodium Substances 0.000 description 23
239000000284 extract Substances 0.000 description 22
239000000047 product Substances 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
239000011541 reaction mixture Substances 0.000 description 20
229960000583 acetic acid Drugs 0.000 description 19
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 18
239000000377 silicon dioxide Substances 0.000 description 18
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 17
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
239000003921 oil Substances 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 15
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
239000012362 glacial acetic acid Substances 0.000 description 14
150000003254 radicals Chemical class 0.000 description 14
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
238000003818 flash chromatography Methods 0.000 description 13
238000003756 stirring Methods 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
239000012267 brine Substances 0.000 description 12
238000004440 column chromatography Methods 0.000 description 12
239000003208 petroleum Substances 0.000 description 12
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
235000006708 antioxidants Nutrition 0.000 description 11
230000003859 lipid peroxidation Effects 0.000 description 11
239000000725 suspension Substances 0.000 description 11
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 10
239000008346 aqueous phase Substances 0.000 description 9
238000001704 evaporation Methods 0.000 description 9
239000000706 filtrate Substances 0.000 description 9
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 9
239000012074 organic phase Substances 0.000 description 9
150000004031 phenylhydrazines Chemical class 0.000 description 9
239000000126 substance Substances 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 8
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 8
239000013543 active substance Substances 0.000 description 8
238000001914 filtration Methods 0.000 description 8
229910000029 sodium carbonate Inorganic materials 0.000 description 8
235000010323 ascorbic acid Nutrition 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
239000007789 gas Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
239000011368 organic material Substances 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000007858 starting material Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
239000012230 colorless oil Substances 0.000 description 6
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
239000005457 ice water Substances 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
239000010410 layer Substances 0.000 description 6
238000010992 reflux Methods 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000002835 absorbance Methods 0.000 description 5
YJROYUJAFGZMJA-UHFFFAOYSA-N boron;morpholine Chemical compound [B].C1COCCN1 YJROYUJAFGZMJA-UHFFFAOYSA-N 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000003638 chemical reducing agent Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
210000003494 hepatocyte Anatomy 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
244000166102 Eucalyptus leucoxylon Species 0.000 description 4
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
229940072107 ascorbate Drugs 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000001569 carbon dioxide Substances 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000001816 cooling Methods 0.000 description 4
239000013058 crude material Substances 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000000605 extraction Methods 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
239000012047 saturated solution Substances 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
238000012360 testing method Methods 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
BEKNOGMQVKBMQN-UHFFFAOYSA-N 2-methyl-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)C(C)CC2=C1 BEKNOGMQVKBMQN-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000003078 antioxidant effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
229910052796 boron Inorganic materials 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000004821 distillation Methods 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
239000011343 solid material Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
ZCAMWXOBYJAHLU-UHFFFAOYSA-N 1h-indene;1h-indole Chemical group C1=CC=C2CC=CC2=C1.C1=CC=C2NC=CC2=C1 ZCAMWXOBYJAHLU-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000002841 Lewis acid Substances 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000032683 aging Effects 0.000 description 2
150000001350 alkyl halides Chemical class 0.000 description 2
150000008051 alkyl sulfates Chemical class 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000012043 crude product Substances 0.000 description 2
JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000019249 food preservative Nutrition 0.000 description 2
239000005452 food preservative Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
208000037906 ischaemic injury Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
150000007517 lewis acids Chemical class 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
238000006263 metalation reaction Methods 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
238000005191 phase separation Methods 0.000 description 2
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
239000005871 repellent Substances 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
230000035899 viability Effects 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
ZLGXGLXFBMIVPU-UHFFFAOYSA-N (2,4-dimethylphenyl)hydrazine;hydron;chloride Chemical compound [Cl-].CC1=CC=C(N[NH3+])C(C)=C1 ZLGXGLXFBMIVPU-UHFFFAOYSA-N 0.000 description 1
HMHWNJGOHUYVMD-UHFFFAOYSA-N (4-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=C(NN)C=C1 HMHWNJGOHUYVMD-UHFFFAOYSA-N 0.000 description 1
LMFPPUVGWDZXMB-UHFFFAOYSA-N (4-propan-2-ylphenyl)hydrazine;hydrochloride Chemical compound Cl.CC(C)C1=CC=C(NN)C=C1 LMFPPUVGWDZXMB-UHFFFAOYSA-N 0.000 description 1
KWRSKZMCJVFUGU-UHFFFAOYSA-N 1h-inden-1-ol Chemical compound C1=CC=C2C(O)C=CC2=C1 KWRSKZMCJVFUGU-UHFFFAOYSA-N 0.000 description 1
RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108030002440 Catalase peroxidases Proteins 0.000 description 1
206010008428 Chemical poisoning Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
206010014523 Embolism and thrombosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
229910016876 Fe(NH4)2(SO4)2 Inorganic materials 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000006587 Glutathione peroxidase Human genes 0.000 description 1
108700016172 Glutathione peroxidases Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
208000028922 artery disease Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QGKIJYBOYMJGHT-UHFFFAOYSA-M azanium;sodium;2,3-dihydroxybutanedioate Chemical compound [NH4+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O QGKIJYBOYMJGHT-UHFFFAOYSA-M 0.000 description 1
PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000002113 chemopreventative effect Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000020335 dealkylation Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000002027 dichloromethane extract Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical class O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000753 hepatic injury Toxicity 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical class C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000000936 membranestabilizing effect Effects 0.000 description 1
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
230000008811 mitochondrial respiratory chain Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000006396 nitration reaction Methods 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000004323 potassium nitrate Substances 0.000 description 1
235000010333 potassium nitrate Nutrition 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000010926 purge Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000007348 radical reaction Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
239000012260 resinous material Substances 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
150000003385 sodium Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000001665 trituration Methods 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
229940041603 vitamin k 3 Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Indole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

DD90341939A 1989-06-22 1990-06-21 Indenoindolverbindungen ii DD297960A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8902274A SE8902274D0 (sv)	1989-06-22	1989-06-22	Indenoidole compounds ii

Publications (1)

Publication Number	Publication Date
DD297960A5 true DD297960A5 (de)	1992-01-30

Family

ID=20376370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90341939A DD297960A5 (de)	1989-06-22	1990-06-21	Indenoindolverbindungen ii

Country Status (34)

Country	Link
EP (1)	EP0409410B1 (pl)
JP (1)	JP3064411B2 (pl)
KR (1)	KR920702679A (pl)
CN (1)	CN1033029C (pl)
AT (1)	ATE135688T1 (pl)
BG (1)	BG60317B2 (pl)
CA (1)	CA2060897A1 (pl)
DD (1)	DD297960A5 (pl)
DE (1)	DE69025998T2 (pl)
DK (1)	DK0409410T3 (pl)
DZ (1)	DZ1428A1 (pl)
ES (1)	ES2084660T3 (pl)
FI (1)	FI100800B (pl)
GR (1)	GR3019779T3 (pl)
HR (1)	HRP920903B1 (pl)
HU (1)	HUT59097A (pl)
IE (1)	IE74682B1 (pl)
IL (1)	IL94830A (pl)
IS (1)	IS3590A7 (pl)
LT (1)	LT3675B (pl)
LV (1)	LV10253B (pl)
MX (1)	MX21244A (pl)
MY (1)	MY107311A (pl)
NO (1)	NO177932C (pl)
NZ (1)	NZ234175A (pl)
PL (1)	PL167761B1 (pl)
PT (1)	PT94468B (pl)
RO (1)	RO111573B1 (pl)
RU (1)	RU2104270C1 (pl)
SE (1)	SE8902274D0 (pl)
SI (1)	SI9011223B (pl)
WO (1)	WO1990015799A1 (pl)
YU (1)	YU122390A (pl)
ZA (1)	ZA904827B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU9301104D0 (en) *	1990-10-16	1993-07-28	Univ Bath	Method for producing tetrahydro-indeno-indole derivatves and pharmaceutical preparatives containing it
JPH0656669A (ja) *	1992-06-11	1994-03-01	Asahi Breweries Ltd	活性酸素消去作用を持つプテリン誘導体製剤
SE9302431D0 (sv) *	1993-07-16	1993-07-16	Ab Astra	Use of indenoindole compounds
AU675141B2 (en) *	1993-07-20	1997-01-23	Adir Et Compagnie	(Thia)cycloalkyl(b)indoles, process for preparing them and pharmaceutical compositions containing them
US6288099B1 (en)	1998-12-04	2001-09-11	American Home Products Corporation	Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
BR9915900A (pt) *	1998-12-04	2001-08-21	American Home Prod	Composto, composição farmacêutica, e, processo para tratar ou inibir distúrbios associados com contração da musculatura lisa.
FR2826009B1 (fr) *	2001-06-13	2003-08-15	Servier Lab	Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1910338B1 (en)	2005-07-14	2010-08-25	Irm, Llc	Heterotetracyclic compounds as tpo mimetics
DE102006047231B4 (de)	2006-10-04	2009-02-12	Hemmerling, Hans-Jörg, Dr.	Substituierte Indeno[1,2-b]indolderivate als neue Hemmstoffe der Protein Kinase CK2 und ihre Verwendung als Tumor Therapeutika, Cytostatika und Diagnostika
EA026149B1 (ru) *	2011-06-16	2017-03-31	Корея Рисерч Инститьют Оф Кемикал Текнолоджи	Производное инданона, его фармацевтически приемлемая соль или оптический изомер, способ его получения и содержащая его фармацевтическая композиция для профилактики или лечения вирусного заболевания
PL3882244T3 (pl)	2012-12-14	2025-06-16	Korea Research Institute Of Chemical Technology	ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH
US12286423B2 (en)	2020-04-20	2025-04-29	Novartis Ag	Antiviral 1,3-di-oxo-indene compounds
CA3176727A1 (en)	2020-04-20	2021-10-28	Novartis Ag	Antiviral 1,3-di-oxo-indene compounds

1989
- 1989-06-22 SE SE8902274A patent/SE8902274D0/xx unknown
1990
- 1990-06-13 IS IS3590A patent/IS3590A7/is unknown
- 1990-06-20 RO RO149127A patent/RO111573B1/ro unknown
- 1990-06-20 WO PCT/GB1990/000949 patent/WO1990015799A1/en not_active Ceased
- 1990-06-20 PL PL90285752A patent/PL167761B1/pl unknown
- 1990-06-20 DK DK90306718.9T patent/DK0409410T3/da active
- 1990-06-20 DE DE69025998T patent/DE69025998T2/de not_active Expired - Fee Related
- 1990-06-20 EP EP90306718A patent/EP0409410B1/en not_active Expired - Lifetime
- 1990-06-20 AT AT90306718T patent/ATE135688T1/de active
- 1990-06-20 IE IE224790A patent/IE74682B1/en not_active IP Right Cessation
- 1990-06-20 DZ DZ900114A patent/DZ1428A1/fr active
- 1990-06-20 MX MX21244A patent/MX21244A/es unknown
- 1990-06-20 CA CA002060897A patent/CA2060897A1/en not_active Abandoned
- 1990-06-20 ES ES90306718T patent/ES2084660T3/es not_active Expired - Lifetime
- 1990-06-20 HU HU904825A patent/HUT59097A/hu unknown
- 1990-06-20 RU SU5010937A patent/RU2104270C1/ru active
- 1990-06-20 JP JP2508940A patent/JP3064411B2/ja not_active Expired - Fee Related
- 1990-06-21 NZ NZ234175A patent/NZ234175A/xx unknown
- 1990-06-21 ZA ZA904827A patent/ZA904827B/xx unknown
- 1990-06-21 IL IL9483090A patent/IL94830A/en not_active IP Right Cessation
- 1990-06-21 DD DD90341939A patent/DD297960A5/de not_active IP Right Cessation
- 1990-06-21 MY MYPI90001050A patent/MY107311A/en unknown
- 1990-06-22 CN CN90104933A patent/CN1033029C/zh not_active Expired - Fee Related
- 1990-06-22 YU YU122390A patent/YU122390A/sh unknown
- 1990-06-22 PT PT94468A patent/PT94468B/pt not_active IP Right Cessation
- 1990-06-22 SI SI9011223A patent/SI9011223B/sl unknown
1991
- 1991-12-19 FI FI915999A patent/FI100800B/fi active
- 1991-12-20 BG BG095667A patent/BG60317B2/bg unknown
- 1991-12-20 NO NO915049A patent/NO177932C/no unknown
- 1991-12-23 KR KR1019910701951A patent/KR920702679A/ko not_active Ceased
1992
- 1992-10-02 HR HRP-1223/90A patent/HRP920903B1/xx not_active IP Right Cessation
1993
- 1993-06-14 LV LVP-93-568A patent/LV10253B/xx unknown
- 1993-08-30 LT LTIP912A patent/LT3675B/lt not_active IP Right Cessation
1996
- 1996-04-29 GR GR960401159T patent/GR3019779T3/el unknown

Also Published As

Publication number	Publication date
IE902247A1 (en)	1991-01-16
NZ234175A (en)	1992-12-23
HU904825D0 (en)	1992-03-30
IE902247L (en)	1990-12-22
NO177932C (no)	1995-12-20
YU122390A (sh)	1992-09-07
HRP920903B1 (en)	1998-06-30
BG60317B2 (bg)	1994-07-25
IL94830A0 (en)	1991-04-15
RU2104270C1 (ru)	1998-02-10
ATE135688T1 (de)	1996-04-15
DE69025998D1 (de)	1996-04-25
JP3064411B2 (ja)	2000-07-12
MY107311A (en)	1995-11-30
PT94468A (pt)	1991-02-08
IL94830A (en)	1996-07-23
PL167761B1 (pl)	1995-10-31
IE74682B1 (en)	1997-07-30
DZ1428A1 (fr)	2004-09-13
LT3675B (en)	1996-01-25
CN1033029C (zh)	1996-10-16
ZA904827B (en)	1991-04-24
DE69025998T2 (de)	1996-08-08
JPH04505923A (ja)	1992-10-15
NO915049D0 (no)	1991-12-20
PT94468B (pt)	1997-12-31
NO177932B (no)	1995-09-11
AU644084B2 (en)	1993-12-02
EP0409410B1 (en)	1996-03-20
CN1051554A (zh)	1991-05-22
MX21244A (es)	1994-03-31
LV10253A (lv)	1994-10-20
HRP920903A2 (hr)	1994-04-30
FI915999A0 (fi)	1991-12-19
WO1990015799A1 (en)	1990-12-27
SI9011223A (en)	1997-10-31
SI9011223B (sl)	1998-08-31
NO915049L (no)	1992-02-21
FI100800B (fi)	1998-02-27
HUT59097A (en)	1992-04-28
AU5836990A (en)	1991-01-08
LTIP912A (en)	1995-03-27
KR920702679A (ko)	1992-10-06
GR3019779T3 (en)	1996-07-31
IS3590A7 (is)	1990-12-23
SE8902274D0 (sv)	1989-06-22
LV10253B (en)	1995-04-20
DK0409410T3 (da)	1996-04-29
PL285752A1 (en)	1991-03-11
ES2084660T3 (es)	1996-05-16
EP0409410A1 (en)	1991-01-23
RO111573B1 (ro)	1996-11-29
CA2060897A1 (en)	1990-12-23

Legal Events

Date	Code	Title	Description
1999-12-23	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69322033T2 (de)	1999-06-17	Kondensierte Pyridin Derivate als Hemmer von Effekten freier Radikaler
DE2718669C2 (pl)	1987-06-11
DE69025998T2 (de)	1996-08-08	Indenoindolverbindungen
DE69533194T2 (de)	2005-08-11	PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
DE69200394T2 (de)	1995-04-27	3-Sulfonylamino-2-(1H)-Chinolinone und deren 7-Azaderivate als anregende Aminosäuren Antagonisten.
IE75716B1 (en)	1997-09-24	Aminocarbonylcarbamates related to physostigmine a process for their preparation and their use as medicaments
KR100234445B1 (ko)	1999-12-15	(((아릴알킬피페리딘-4-일)메틸)-2a,3,4,5-테트라하이드로-1(2h)-아세나프틸렌-1-온 및 관련 화합물,이의 제조방법 및 이를 포함하는 약제학적 조성물
DE69629341T2 (de)	2004-06-09	Pyrrolocarbazolderivate
DD298388A5 (de)	1992-02-20	Indenoindolverbindungen
DE60002043T2 (de)	2004-02-19	4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indol-1-carboxamid-derivate, ihre herstellung und therapeutische verwendung
DE10053813A1 (de)	2002-05-08	Neue Verwendung von Sulfonamiden
DE69521887T2 (de)	2001-11-22	Verbessertes verfahren zur herstellung von 6,9[(zaminoethyl)amino]benzo[g]isochinoline-5,10 dione und sein dimaleinsaeure salz
FR2467848A1 (fr)	1981-04-30	Sels d'acides 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxalinecarboxyliques et d'amines steriquement encombrees, leur preparation et leur utilisation therapeutique
US5516788A (en)	1996-05-14	Tetrahydroindenoindole compounds useful in the treatment of conditions associated with free radical formation
CZ65393A3 (en)	1994-02-16	Indenoindole derivative, process of its preparation and pharmaceutical preparation in which said derivative is comprised
DE10226592B4 (de)	2004-07-29	Tumorhemmende Platin(II)-oxalato-Komplexe
DE68921470T2 (de)	1995-08-03	Diazabicycloalkan-derivate.
AU644084C (en)	1995-01-05	Indenoindole compounds II
EP0937089A1 (de)	1999-08-25	Neue knoevenagel-kondensationsprodukte, verfahren zu deren herstellung und verwendung
LU81797A1 (fr)	1980-01-25	Combinations antivirales
DE602005004278T2 (de)	2008-12-24	Arylpyrrol mit antitubulinwirkung, arylfulran- und arylthiopenderivate, verfahren zur herstellung und verwendung als antimitotikum
US2803627A (en)	1957-08-20	Therapeutic quinoline compounds
DE10253720A1 (de)	2004-07-29	10-Phenylimino-9(10H)-anthracenone als neue Inhibitoren der Tubulin-Polymerisation
DE10253746A1 (de)	2004-06-03	10-Benzyliden-1,8-dichlor-9(10H)-anthracenone als neue Inhibitoren der Tubulin-Polymerisation
CS202088B2 (en)	1980-12-31	Method of producing tetrameric complex of malonylurea derivatives